AASLD 2011: TMC435 + Interferon/Ribavirin Raises Cure Rates for Naive and Experienced Hepatitis C Patients

Adding the HCV NS3/4A protease inhibitor TMC435 to standard pegylated interferon/ribavirin therapy led to high rates of sustained virological response  for both treatment-naive hepatitis C patients and prior non-responders, according to data released last week at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011).

AASLD 2011: Adding Tenofovir to Entecavir Offers No Additional Benefit for Hepatitis B Patients

Dual therapy using entecavir (Baraclude) plus tenofovir (Viread) did not work better than entecavir alone in a 3-year study of previously untreated chronic hepatitis B patients, according to a presentation at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) last week in San Francisco.

AASLD 2011: BI 201335 Performs Well with Standard Therapy

Once-daily BI 201335 added to pegylated interferon/ribavirin for 24 weeks produced consistently high SVR rates across difficult-to-treat chronic hepatitis C patient subgroups, according to findings from the SILEN-C1 study presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) last week in San Francisco. A follow-up study showed that rapid responders did equally well with 12 or 24 weeks of treatment.

AASLD 2011: Telaprevir Improves Hepatitis C Treatment Response for HIV/HCV Coinfected People

Adding the hepatitis C virus (HCV) protease inhibitor telaprevir (Incivek) to pegylated interferon plus ribavirin increased virological response rates at 24 weeks for HIV/HCV coinfected patients, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco.

AASLD 2011: HCV Direct-Acting Antivirals Boost Interferon Response Rates

Several studies at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) last week in San Francisco showed that adding experimental direct-acting antiviral (DAA) agents to pegylated interferon plus ribavirin increases virological response rates for people with chronic hepatitis C.

BI 201335 Performs Well with Standard Therapy

TMC435 + Pegylated Interferon/Ribavirin

PSI-7977 + Pegylated Interferon/Ribavirin

12-week Daclatasvir + Pegylated Interferon/Ribavirin

Danoprevir + Pegylated Interferon/Ribavirin

AASLD 2011: New NS5A Inhibitor PPI-461 Shows Promising Safety and Efficacy in Brief Study

Presidio's hepatitis C virus (HCV) NS5A inhibitor candidate PPI-461 demonstrated rapid and potent antiviral activity in a 3-day study, but resistance may be a problem, according to a study presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco.

AASLD 2011: Do Hepatitis C Patients with Cirrhosis Benefit from Adding Telaprevir?

Adding telaprevir to pegylated interferon/ribavirin increased the likelihood of a cure for genotype 1 chronic hepatitis C patients with liver cirrhosis in the REALIZE trial, according to data presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) last week in San Francisco.

All-Oral Regimens -- The Future of Hepatitis C Treatment

Attendees at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco got a glimpse of the future of chronic hepatitis C therapy, as several researchers presented data from studies of all-oral direct-acting antiviral (DAA) regimens -- without interferon and its notoriously difficult side effects.

NEJM: High SVR Rate with Daclatasvir + Asunaprevir

AASLD: Daclatasvir + Asunaprevir Suppresses HCV in Null Responders

AASLD: PSI-7977 + Ribavirin Cures Hepatitis C in 12 Weeks

AASLD: BI 201355 + BI 201127 + Ribavirin Looks Good in SOUND-C